Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.
Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Dasgupta Y, et al. Among authors: hantschel o. Blood. 2016 Apr 28;127(17):2131-43. doi: 10.1182/blood-2015-11-681171. Epub 2016 Feb 10. Blood. 2016. PMID: 26864341 Free PMC article.
CDK6 degradation hits Ph+ ALL hard.
Hantschel O. Hantschel O. Blood. 2020 Apr 30;135(18):1512-1514. doi: 10.1182/blood.2020005136. Blood. 2020. PMID: 32353124 Free article. No abstract available.
Targeting BCR-ABL and JAK2 in Ph+ ALL.
Hantschel O. Hantschel O. Blood. 2015 Feb 26;125(9):1362-3. doi: 10.1182/blood-2014-12-617548. Blood. 2015. PMID: 25721043 Free article.
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. Sherbenou DW, et al. Among authors: hantschel o. Blood. 2010 Oct 28;116(17):3278-85. doi: 10.1182/blood-2008-10-183665. Epub 2010 Jun 2. Blood. 2010. PMID: 20519627 Free PMC article.
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.
Mian AA, Haberbosch I, Khamaisie H, Agbarya A, Pietsch L, Eshel E, Najib D, Chiriches C, Ottmann OG, Hantschel O, Biondi RM, Ruthardt M, Mahajna J. Mian AA, et al. Among authors: hantschel o. Ann Hematol. 2021 Aug;100(8):2023-2029. doi: 10.1007/s00277-020-04357-z. Epub 2021 Jun 10. Ann Hematol. 2021. PMID: 34110462 Free PMC article.
Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
Lamontanara AJ, Gencer EB, Kuzyk O, Hantschel O. Lamontanara AJ, et al. Among authors: hantschel o. Biochim Biophys Acta. 2013 Jul;1834(7):1449-59. doi: 10.1016/j.bbapap.2012.12.009. Epub 2012 Dec 28. Biochim Biophys Acta. 2013. PMID: 23277196 Review.
Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms.
Duarte DP, Lamontanara AJ, La Sala G, Jeong S, Sohn YK, Panjkovich A, Georgeon S, Kükenshöner T, Marcaida MJ, Pojer F, De Vivo M, Svergun D, Kim HS, Dal Peraro M, Hantschel O. Duarte DP, et al. Among authors: hantschel o. Nat Commun. 2020 May 8;11(1):2319. doi: 10.1038/s41467-020-16128-5. Nat Commun. 2020. PMID: 32385234 Free PMC article.
77 results